Construct Validity of the IDEOM Musculoskeletal Questionnaire (IDEOM MSK-Q) Using Data from the Cohort for Psoriasis and Psoriatic Arthritis Registry (COPPAR)

Lourdes Perez Chada¹, Ruogu Li², vivi feathers², Kumiko Schnock², Helen Early², Grace Carter², Neda Shahriari², Arianna Zhang², Jing Cui³, Michael Weinblatt⁴, Nancy Shadick², Alice Gottlieb⁵ and Joseph Merola⁶, ¹Harvard Medical School, Wayland, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ⁵Icahn School of Medicine at Mount Sinai, Department of Dermatology, Seattle, WA, ⁶UT Southwestern Medical Center, Newton, MA

Meeting: ACR Convergence 2024

Keywords: Dermatology, Patient reported outcomes, Psoriatic arthritis, skin, Spondyloarthropathies

Session Information

Date: Monday, November 18, 2024

Title: Patient Outcomes, Preferences, & Attitudes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Patients with psoriasis often present with musculoskeletal (MSK) symptoms, yet validated instruments to measure MSK symptoms in this population are limited. The IDEOM MSK-Q is a novel patient-reported outcome measure to evaluate MSK symptoms and their impact in individuals with psoriasis with or without concomitant psoriatic arthritis (PsA). The instrument has 3 subscores: Intensity of MSK Symptoms (3 items), Impact of MSK Symptoms (4 items), and Intensity of Fatigue (1 item). This study evaluated the construct validity of the IDEOM MSK-Q in a real-world cohort.

Methods: Data for analysis was obtained from the Cohort of Psoriasis for Psoriatic Arthritis Registry (COPPAR). We tested a-priori hypotheses about the correlation of the IDEOM MSK-Q subscores with scores of instruments measuring similar (r > 0.5) or related but dissimilar (r > 0.3) constructs (convergent validity) using Spearman’s rank correlation. To determine known-groups validity, we tested a-priori hypotheses about differences in the IDEOM MSK-Q subscores among groups based on disease severity as defined by the Psoriatic Arthritis Impact of Disease (PsAID-9), Minimal Disease Activity (MDA), Disease Activity in Psoriatic Arthritis (DAPSA), Routine Assessment Patient Index Data-3 (RAPID3). The median scores for each subscore of the IDEOM MSK-Q were compared among groups using Wilcoxon rank sum and Kruskal Wallis H tests. Construct validity was considered sufficient if at least 75% of the correlations aligned with the hypotheses.

Results: A total of 79 participants with psoriasis-only and 166 patients with psoriasis and concomitant PsA were included. In the psoriasis group, the mean age was 54.8 (SD 16.5), and 43% were female. In the PSA group, the mean age was 56.9 (SD 12.8), and 53.6% were female. Overall, more than 90% of correlations were aligned with hypotheses (Tables 1 and 2). Among patients with PsA, the Intensity of MSK Symptoms subscore strongly correlated with Pain Numeric Rating Scale (r=0.76) and tender joint count (r=0.58). The Impact of MSK Symptoms subscore strongly correlated with PsAID9 (r=0.75) and RAPID3 (r=0.69). Among patients with PsA and PsO, The Impact of MSK Symptoms subscore and the Fatigue subscore strongly correlated with EQ5D Index Score (r=-0.59 – -0.69) and FACIT-Fatigue (0.60-0.70), respectively. The IDEOM MSK-Q differentiated among individuals with different levels of PsA severity as defined by PsAID-9, MDA, DAPSA, and RAPID3 (Table 3).

Conclusion: Overall, the IDEOM MSK-Q has sufficient construct validity to assess musculoskeletal symptoms in patients with psoriatic disease. Assessments of other critical measurement properties, including test-retest reliability and responsiveness, are currently in progress.

Table 1. Spearman’s correlations between the IDEOM MSK-Q subscores and other measures assessing similar constructs among patients with PsA and psoriasis

Table 2. Spearman’s correlations between the IDEOM MSK-Q subscores and other measures assessing related (but dissimilar) constructs among patients with PsA and psoriasis

Table 3. Known-groups validity of the IDEOM MSK-Q Subscores

Disclosures: L. Perez Chada: Group for Research And Assessment for Psoriasis and Psoriatic Arthritits, 5; R. Li: None; v. feathers: None; K. Schnock: AbbVie/Abbott, 5, Bristol-Myers Squibb(BMS), 5; H. Early: None; G. Carter: None; N. Shahriari: None; A. Zhang: None; J. Cui: None; M. Weinblatt: AbbVie/Abbott, 2, 5, Aclaris, 2, Amgen, 2, Aqtual, 2, 5, Bristol-Myers Squibb(BMS), 2, 5, Canfite, 11, Eli Lilly, 2, GlaxoSmithKlein(GSK), 2, Inmedix, 11, Johnson and Johnson, 2, 5, Novartis, 2, Pfizer, 2, Prometheus, 2, Rani, 2, Revolo, 2, Sanofi, 2, Sci Rhom, 2, Scipher, 2, 11, Set Point, 2; N. Shadick: Abbbvie, 5, AQtual, 5, BMS, 5, Janssen, 5; A. Gottlieb: Amgen, 1, 2, AnaptypsBio, 1, 2, Avotres Therapeutics, 1, 2, Boehringer Ingelheim, 1, 2, Bristol Myers Squibb, 1, 2, 5, Dice Therapeutics, 1, 2, Eli Lilly, 1, 2, Highlights Therapeutics, 1, 2, 5, Janssen, 1, 2, 5, Novartis, 1, 2, Sanofi, 1, 2, Teva, 1, 2, UCB, 1, 2, 5, Xbiotech, 1, 2; J. Merola: AbbVie, 12, Consultant and/or investigator, Amgen, 12, Consultant and/or investigator, AstraZeneca, 12, Consultant and/or investigator, Biogen, 12, Consultant and/or investigator, Boehringer Ingelheim, 12, Consultant and/or investigator, Bristol Myers Squibb, 12, Consultant and/or investigator, Dermavant, 12, Consultant and/or investigator, Eli Lilly, 12, Consultant and/or investigator, Janssen, 12, Consultant and/or investigator, MoonLake, 12, Consultant and/or investigator, Novartis, 12, Consultant and/or investigator, Pfizer, 12, Consultant and/or investigator, Sanofi-Regeneron, 12, Consultant and/or investigator, Sun Pharma, 12, Consultant and/or investigator, UCB, 12, Consultant and/or investigator.

To cite this abstract in AMA style:

Perez Chada L, Li R, feathers v, Schnock K, Early H, Carter G, Shahriari N, Zhang A, Cui J, Weinblatt M, Shadick N, Gottlieb A, Merola J. Construct Validity of the IDEOM Musculoskeletal Questionnaire (IDEOM MSK-Q) Using Data from the Cohort for Psoriasis and Psoriatic Arthritis Registry (COPPAR) [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/construct-validity-of-the-ideom-musculoskeletal-questionnaire-ideom-msk-q-using-data-from-the-cohort-for-psoriasis-and-psoriatic-arthritis-registry-coppar/. Accessed .

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/construct-validity-of-the-ideom-musculoskeletal-questionnaire-ideom-msk-q-using-data-from-the-cohort-for-psoriasis-and-psoriatic-arthritis-registry-coppar/